Paul M McGregor 3rd
Overview
Explore the profile of Paul M McGregor 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verner E, Jackson J, Severson E, Valkenburg K, Greer A, Riley D, et al.
J Mol Diagn
. 2023 Apr;
25(7):477-489.
PMID: 37068734
Genomic profiling is critical for precision oncology to guide treatment decisions. Liquid biopsy testing is a complementary approach to tissue testing, particularly when tissue is not readily available. The Labcorp...
2.
Keefer L, White J, Wood D, Gerding K, Valkenburg K, Riley D, et al.
Nat Commun
. 2022 May;
13(1):2830.
PMID: 35595835
The lack of validated, distributed comprehensive genomic profiling assays for patients with cancer inhibits access to precision oncology treatment. To address this, we describe elio tissue complete, which has been...
3.
Tricoli J, Boardman L, Patidar R, Sindiri S, Jang J, Walsh W, et al.
Cancer
. 2017 Dec;
124(5):1070-1082.
PMID: 29194591
Background: It is possible that the relative lack of progress in treatment outcomes among adolescent and young adult (AYA) patients with cancer is caused by a difference in disease biology...
4.
Chang L, Das B, Lih C, Si H, Camalier C, McGregor 3rd P, et al.
Cancer Inform
. 2016 May;
15:65-71.
PMID: 27147817
With rapid advances in DNA sequencing technologies, whole exome sequencing (WES) has become a popular approach for detecting somatic mutations in oncology studies. The initial intent of WES was to...
5.
Sims D, Harrington R, Polley E, Forbes T, Mehaffey M, McGregor 3rd P, et al.
J Mol Diagn
. 2016 Apr;
18(3):336-349.
PMID: 27105923
Although next-generation sequencing technologies have been widely adapted for clinical diagnostic applications, an urgent need exists for multianalyte calibrator materials and controls to evaluate the performance of these assays. Control...
6.
Kummar S, Oza A, Fleming G, Sullivan D, Gandara D, Naughton M, et al.
Clin Cancer Res
. 2015 Jan;
21(7):1574-82.
PMID: 25589624
Purpose: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relative contribution of...